Table 1.

ANOVA test results from the comparison between male and female familial breast cancer and sporadic tumors

	fMBC	fFBC
	BRCAX	BRCA-related	BRCAX	sporadic	P
hsa-miR-106b	9.34 ± 0.57	5.88 ± 2.72	5.09 ± 2.48	5.69 ± 2.63	5.49E-05
hsa-miR-1259	2.15 ± 0.15	2.31 ± 0.15	2.47 ± 0.24	2.27 ± 0.18	8.93E-05
hsa-miR-125a-3p	6.01 ± 1.04	4.11 ± 1.22	3.76 ± 1.21	3.83 ± 1.36	1.00E-05
hsa-miR-1271	3.58 ± 0.81	3.01 ± 0.44	2.62 ± 0.30	2.73 ± 1.36	1.59E-05
hsa-miR-1274a	6.83 ± 1.78	3.73 ± 1.68	2.88 ± 0.98	3.65 ± 1.23	2.99E-10
hsa-miR-1274b	9.44 ± 1.38	5.78 ± 2.48	4.31 ± 2.04	5.69 ± 2.30	1.70E-07
hsa-miR-128	4.32 ± 1.56	2.95 ± 0.74	2.57 ± 0.33	2.80 ± 0.63	4.66E-07
hsa-miR-140-5p	3.13 ± 0.83	2.58 ± 0.46	2.30 ± 0.15	2.36 ± 0.20	1.83E-06
hsa-miR-143-star	4.03 ± 1.43	2.51 ± 0.38	2.53 ± 0.40	2.53 ± 0.42	5.70E-09
hsa-miR-143	10.12 ± 1.36	6.82 ± 2.58	6.08 ± 2.66	6.11 ± 2.87	8.81E-05
hsa-miR-148a	4.45 ± 1.62	2.83 ± 0.57	2.66 ± 0.55	3.11 ± 1.08	9.25E-06
hsa-miR-148b	3.34 ± 0.99	2.50 ± 0.23	2.46 ± 0.26	2.48 ± 0.34	1.53E-06
hsa-miR-152	7.76 ± 1.36	4.82 ± 1.84	4.07 ± 1.82	4.52 ± 1.82	1.11E-06
hsa-miR-15a	6.72 ± 0.87	3.95 ± 1.27	3.20 ± 1.05	3.88 ± 1.41	1.39E-10
hsa-miR-17-star	4.43 ± 0.68	3.12 ± 0.95	2.58 ± 0.44	2.70 ± 0.56	1.73E-10
hsa-miR-181c-star	3.10 ± 0.82	2.43 ± 0.28	2.51 ± 0.31	2.41 ± 0.24	2.69E-05
hsa-miR-188-5p	3.19 ± 0.43	2.55 ± 0.35	2.50 ± 0.32	2.74 ± 0.40	1.46E-05
hsa-miR-192	3.75 ± 0.82	2.56 ± 0.30	2.49 ± 0.40	2.55 ± 0.49	4.51E-10
hsa-miR-193a-3p	5.25 ± 1.22	2.65 ± 0.49	2.75 ± 0.65	2.76 ± 0.53	0
hsa-miR-194	4.98 ± 1.53	3.33 ± 0.94	3.28 ± 1.04	3.09 ± 0.83	1.11E-05
hsa-miR-19a	3.10 ± 0.48	2.58 ± 0.36	2.55 ± 0.26	2.53 ± 0.32	6.38E-05
hsa-miR-19b	7.22 ± 1.16	4.99 ± 1.91	3.66 ± 1.49	4.33 ± 1.80	1.15E-06
hsa-miR-200a-star	4.16 ± 0.89	2.90 ± 0.54	2.75 ± 0.44	2.93 ± 0.45	3.10E-09
hsa-miR-200a	6.75 ± 1.87	4.10 ± 1.47	3.55 ± 1.49	3.68 ± 1.53	6.00E-07
hsa-miR-203	6.09 ± 2.68	3.97 ± 1.76	3.31 ± 1.25	3.26 ± 1.24	2.68E-05
hsa-miR-21-star	5.71 ± 1.41	3.58 ± 1.12	3.19 ± 1.09	3.28 ± 0.99	3.98E-08
hsa-miR-21	7.05 ± 2.00	4.86 ± 1.91	3.67 ± 1.50	4.79 ± 2.04	8.21E-05
hsa-miR-214-star	3.90 ± 1.38	2.62 ± 0.69	2.54 ± 0.47	2.61 ± 0.49	4.32E-06
hsa-miR-22-star	3.12 ± 0.63	2.55 ± 0.24	2.60 ± 0.31	2.49 ± 0.21	8.00E-06
hsa-miR-22	9.86 ± 0.92	6.35 ± 2.64	5.40 ± 2.83	6.34 ± 2.87	1.20E-04
hsa-miR-24-2-star	4.11 ± 1.00	2.96 ± 0.79	2.67 ± 0.42	2.83 ± 0.61	1.13E-06
hsa-miR-27b-star	3.06 ± 0.38	2.49 ± 0.39	2.49 ± 0.33	2.54 ± 0.34	1.00E-04
hsa-miR-29b	3.74 ± 1.31	2.40 ± 0.21	2.42 ± 0.23	2.47 ± 0.38	4.21E-09
hsa-miR-29c-star	3.66 ± 1.08	2.41 ± 0.32	2.33 ± 0.25	2.43 ± 0.27	6.70E-11
hsa-miR-29c	4.27 ± 1.48	2.56 ± 0.35	2.52 ± 0.28	2.55 ± 0.48	9.49E-11
hsa-miR-30b	6.59 ± 1.87	4.25 ± 1.57	3.82 ± 1.47	4.34 ± 1.76	1.44E-04
hsa-miR-30c-2-star	4.27 ± 1.22	3.23 ± 0.99	2.75 ± 0.61	2.98 ± 0.55	1.90E-05
hsa-miR-30e	4.95 ± 1.35	3.23 ± 0.81	2.68 ± 0.43	3.07 ± 0.72	3.36E-10
hsa-miR-3160	2.77 ± 0.41	2.47 ± 0.24	2.32 ± 0.23	2.44 ± 0.20	1.26E-04
hsa-miR-3172	6.25 ± 0.50	3.74 ± 1.34	3.58 ± 1.45	4.15 ± 1.79	1.48E-05
hsa-miR-331-3p	5.18 ± 0.68	3.98 ± 1.24	3.57 ± 1.11	3.49 ± 0.95	8.87E-05
hsa-miR-339-3p	6.00 ± 0.56	4.34 ± 1.39	3.75 ± 1.55	3.97 ± 1.47	1.59E-04
hsa-miR-375	9.66 ± 1.24	5.46 ± 2.70	5.39 ± 2.84	5.14 ± 2.79	2.16E-05
hsa-miR-4317	3.40 ± 0.38	2.74 ± 0.35	2.63 ± 0.31	2.61 ± 0.27	2.92E-09
hsa-miR-451	4.65 ± 1.10	3.32 ± 0.81	3.06 ± 0.72	3.47 ± 0.70	6.66E-06
hsa-miR-455-5p	2.99 ± 0.39	2.39 ± 0.27	2.44 ± 0.22	2.46 ± 0.20	6.54E-08
hsa-miR-497	6.92 ± 1.60	3.79 ± 1.46	3.50 ± 1.37	3.86 ± 1.49	2.62E-08
hsa-miR-551b-star	4.99 ± 0.95	4.12 ± 0.91	3.69 ± 0.99	4.96 ± 1.03	5.20E-05
hsa-miR-590-3p	2.04 ± 0.12	2.25 ± 0.15	2.36 ± 0.20	2.28 ± 0.22	1.86E-04
hsa-miR-660	4.29 ± 1.19	3.11 ± 0.46	2.91 ± 0.65	3.19 ± 0.73	1.88E-05
hsa-miR-769-5p	4.38 ± 0.72	2.75 ± 0.46	2.64 ± 0.46	2.67 ± 0.41	7.77E-16
hsa-miR-887	3.92 ± 1.18	2.78 ± 0.55	2.68 ± 0.49	2.85 ± 0.57	9.95E-06
hsa-miR-98	4.35 ± 0.87	3.22 ± 0.69	3.11 ± 0.79	2.98 ± 0.63	6.39E-06

fMBC: familial male breast cancer; fFBC: familial female breast cancer. Data are reported as mean log₂[intensity values] ± standard deviation.